Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (321-330 of 362) with videos related to

Pageof 37
Sort By:
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2023
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma DatabaseIsabelle Opitz, Andrea Bille, Urania Dafni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical ArtifactsDaniel Kazdal, Volker Endris, Michael Allgäuer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Clinical Lung Cancer|May 14, 2024
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry AnalysisAmit A Kulkarni, Cassandra Hennessy, Grace Wilson, et al.
JCO Precision Oncology|February 12, 2025
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape ProjectMartina Haberecker, Jan H Rüschoff, Charitini Andriakopoulou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2020
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 PandemicAnne-Marie C Dingemans, Ross A Soo, Abdul Rahman Jazieh, et al.
Lung Cancer (Amsterdam, Netherlands)|November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
Pageof 37

Showing results (321-330 of 362) with videos related to

Sort By:
Pageof 37
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2023
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma DatabaseIsabelle Opitz, Andrea Bille, Urania Dafni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical ArtifactsDaniel Kazdal, Volker Endris, Michael Allgäuer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Clinical Lung Cancer|May 14, 2024
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry AnalysisAmit A Kulkarni, Cassandra Hennessy, Grace Wilson, et al.
JCO Precision Oncology|February 12, 2025
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape ProjectMartina Haberecker, Jan H Rüschoff, Charitini Andriakopoulou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2020
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 PandemicAnne-Marie C Dingemans, Ross A Soo, Abdul Rahman Jazieh, et al.
Lung Cancer (Amsterdam, Netherlands)|November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
Pageof 37